Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIn the SURMOUNT-1 trial, adults taking tirzepatide 15mg lost an average of around 20–21% of their body weight over 72 weeks — roughly 22–23 kg for someone starting at 110 kg. That figure comes from a New England Journal of Medicine study of 2,539 adults and is the most cited benchmark for how much weight you can lose on Mounjaro. Lower doses produced meaningful results too: around 15% average loss at 5mg and 19% at 10mg, both well above placebo. What you'll actually lose depends on your starting weight, the dose you reach, how long you stay on treatment, and the lifestyle changes you make alongside it. Mounjaro is a prescription-only medicine; a clinician has to assess whether it's right for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
SURMOUNT-1 remains the bedrock evidence. Over 72 weeks, tirzepatide at 15mg produced average body-weight reductions of around 20–21% against placebo, a figure that NICE cited in its December 2024 appraisal of tirzepatide (TA1026) when recommending Mounjaro for use in adults with obesity. The 5mg arm averaged roughly 15% loss; the 10mg arm around 19%. Every active arm beat placebo significantly. Those numbers cover around 2,539 participants, so when sources describe the SURMOUNT programme as involving thousands of adults, that is precisely what they mean.
A later head-to-head, the SURMOUNT-5 trial, compared tirzepatide directly with semaglutide 2.4mg over 72 weeks. Tirzepatide produced greater average weight reduction. That result shaped both the NICE appraisal and the clinical conversation about which medicine to start with, though which suits any individual is a prescriber's call, not a headline's.
Trial averages are real data from real people, but they are still averages. Some participants lost considerably more; others less. Starting BMI, biological response, dose reached, and consistency with diet and activity all shift the outcome. If you want a sense of what the evidence suggests for the 5mg dose specifically, our breakdown of 5mg results covers the data in more detail.
Mounjaro's licensed dose ladder runs from 2.5mg up through 5, 7.5, 10, 12.5, to 15mg. The first pen's job is settling your system, not producing dramatic loss. Most people spend the first few weeks adjusting to the medicine, appetite begins to fall, but the biggest results accumulate once a therapeutic dose is reached and maintained. A prescriber, not you, decides when and whether to move up.
This matters for expectations. Someone who reads a 20% average loss figure and expects it by month two will be disappointed. The SURMOUNT-1 participants who reached that average were on treatment for 72 weeks, many at the highest dose. What you lose and when is shaped as much by the pace of titration and your individual response as by the medicine's ceiling.
Real appetite suppression (eating noticeably less, feeling full faster, thinking about food differently) is what drives the loss mechanically. Tirzepatide activates both GLP-1 and GIP receptors, which slows gastric emptying and reduces hunger signals. Our Mounjaro overview explains the mechanism clearly if you want the fuller picture. The point here is that dose and duration are the two levers the evidence consistently identifies as the biggest predictors of how much weight you ultimately lose. If you're curious about how much weight you can lose on the 2.5mg starting dose, we've broken down what the evidence shows at that early stage. For a broader look across all doses, our guide to how much you can lose on Mounjaro overall pulls together the full picture from the trial data.
A lot of people searching how much weight they can lose on Mounjaro are also, quietly, weighing up whether the cost is worth it. That is a fair thing to wonder. Eli Lilly raised Mounjaro's UK list price substantially from September 2025 (the highest dose's list price rose from around £122 to around £330 per four-week pen) and private market prices have tracked that upward, typically ranging roughly £149 to £375 per month depending on dose and provider, as widely reported at the time.
What those headline figures often do not include: the consultation fee, a separate prescription charge, delivery costs, and any ongoing clinical support when questions arise between doses. Add those up and the quoted per-pen number can look quite different from the real monthly outlay. Our Mounjaro pricing page sets out what an all-inclusive private cost actually covers.
nume is deliberately not the cheapest option available. One price covers the consultation, the prescription, next-working-day tracked delivery, and seven-day aftercare, no subscription, no auto-renewal, clinical re-review before every repeat. For a prescription medicine where supply-chain integrity and clinical oversight are part of what keeps you safe, price is the wrong test to run first. The MHRA has consistently warned that fake Mounjaro pens circulate online; some have contained incorrect substances. Verified supply through a GPhC-registered pharmacy is not a premium, it is the baseline. If you are weighing up other routes, this page on Mounjaro alternatives covers what's licensed and available in the UK.
The evidence suggests that people who reach and maintain a therapeutic dose of tirzepatide alongside lifestyle changes can expect meaningful, sustained weight loss over 12 to 18 months. How much is individual. The trial data gives you the distribution; your prescriber gives you the clinical picture.
At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber, you can see our clinical team at our clinical team page. If you're approved, treatment is dispatched the same day for orders placed before 12pm, arriving with DPD the next working day. The eligibility check takes minutes and costs nothing. Check your eligibility and see whether Mounjaro is the right fit clinically before you make any decision about cost.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.